Recursion Pharmaceuticals Inc. surged as breakthrough AI-driven drug discovery progress fueled bullish sentiment, and stocks ...

Recursion Pharmaceuticals Inc. stocks have been trading up by 15.41 percent amid heightened optimism over its AI-driven drug ...

Recursion’s August business update highlighted that Genentech opted its first neuroscience target into an early discovery ...

Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.70, marking a -1.2% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.77%. On ...

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive ...

Recursion Pharmaceuticals (RXRX) closed at $4.05 in the latest trading session, marking a +2.02% move from the prior day. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq ...

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan ...

- Recursion Pharmaceuticals RXRX+16.63% (RXRX) surges 16.38% on heavy volume, trading near $4.83 intraday high. - Extended 2029 Tempus AI TEM +8.11% partnership replaces $84M potential fees with $42M ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Tempus and Recursion deepen their partnership with a new license agreement for Recursion’s RNA Foundation Model, following a $42 million commitment to data collaboration.